Osteonecrosis is one of the 14 medically-approved conditions for using hyperbaric oxygen therapy. Hospitals and medical centers will typically treat this condition with daily sessions at 2.4 to 2.5 ATA. These higher pressures (above 2.0 ATA) can give rise to a greater incidence of complications, including oxygen toxicity. Bearing this in mind, the standard protocol remains 2.4 ATA due to it's effectiveness. In this case report, a 36 year old female was not able to pressurize to these higher depths and instead could only get to 1.6 ATA. She continued daily sessions at 1.6 ATA and after 20 sessions, her symptoms were relived significantly. After 50 sessions, her symptoms were relived almost completely. Both CT and MRI imaging confirmed this successful intervention. This publications should give rise to more research on pressure protocols <view study> Read Less

Telomere length serves as a biological clock to determine our lifespan.  Every year, our telomeres (the ends of our DNA) get shorter until they finally shorten to a length that leads to our mortality. Over the past few decades, researchers and drug companies have focused (and invested substantial capital) on this  key biological determinant (telomere length) in the hopes of being able to stop and reverse the aging process. Since many age-related diseases (like cancer, cardiovascular diseases, diabetes and Alzheimer’s) are also linked to shortened telmeres, it is easy to see why so many drug and nutritional companies have been working hard on finding a cure to stop and reverse the shortening of telomeres. Hyperbaric oxygen therapy has already been demonstrated in clinical studies to help the aging population by reducing the signs of aging and age-related diseases. In 2006, a landmark study showed an 800% increase in stem cell mobilization from a course of hyperbaric oxygen therapy. This gave us a much better understanding of the physiological benefits of this procedure in relation to the aging process. Today we have even more information as a second landmark study has been published on the effects of hyperbaric  therapy in regards to telomere length. In this study, a 3 month course of hyperbaric therapy produced a profound increase in telomere length by 20% - 38%. (This is higher than any other intervention currently available). The hyperbaric protocol used to produce these benefits included 60 hyperbaric sessions (each at 90 minute sessions at 2.0 ATA  with 3 air breaks). This exciting new study will surely lead to many more telomere-based studies in the field of hyperbaric oxygen therapy and further help to advance our knowledge of this therapy.  <View Full Study in the JOURNAL OF AGING> Due to the significance of this study, it has quickly been picked up by many news associations like the following:

• <view in the Independent>
• <view in yahoo news>
• <view in the telegraph>
• <view in aljazeera>
• <view in Science alert>
• <view in Neuroscience news>

Read Less

32 professional or semi-professional rugby players with grade 2 MCL injury of the knee took part of this study and the ones that were treated with hyperbaric oxygen therapy reported less pain and more importantly were able to return to play quicker. Professional athletes of all sports should take note of this study. <view study> Read Less

A 14 day course of hyperbaric pretreatment for 14 days (once a day at 2.5 ATA) improved mitochondrial morphology and significantly increased the levels of ATP. This study shows a “restoration of mitochondrial function” and helping to improve cellular energy levels. <view study> Read Less

The benefits of hyperbaric oxygen therapy for dramatic brain injury (TBI) has been confirmed by many studies. Now the question is “what is the best dose (ie, pressure protocol) to achieve the optimal benefits. As new research becomes available, it appears that the lower the pressure, the stronger the benefits. This study confirms the recent data, by showing that 1.6 ATA hyperbaric intervention was superior to 2.2ATA for neurological impairment and the restoration of symptoms following TBI. Researchers in this study suggested that “for the first time that 1.6 ATA HBO has an important protective role in inhibiting both the cytotoxic and the pro-inflammatory actions of histones in the early stage of secondary brain injury”. <view study> Read Less